ERBB2 and lung adenocarcinoma: The tyrosine kinase inhibitors erlotinib and gefitinib show significant clinical responses in lung adenocarcinoma patients harbouring EGFR activating mutations [40], whereas dacomitinib, a pan-HER tyrosine kinase inhibitor has been shown to be beneficial in HER2-mutated lung tumours [41].